Typical Testing Data/Standard Curve (for reference only)
Human Mycoplasma pneumoniae IgA ELISA Kit | IgA elisa kit
Recombinant Mycoplasma pneumoniae IgA
Reactivity
Human
Applications
ELISA
Synonyms
Mycoplasma pneumoniae IgA; Recombinant Mycoplasma pneumoniae IgA; RECOMBINANT MYCOPLASMA PNEUMONIAE IGA (SEROMP); IgA elisa kit
Reactivity
Human
Applicable Applications for IgA elisa kit
ELISA (EIA)
Samples
Human serum
Preparation and Storage
Store at 2-8 degree C
Typical Testing Data/Standard Curve (for reference only)
Typical Testing Data/Standard Curve (for reference only)
Related Product Information for IgA elisa kit
Intended Uses: SeroMP™ Recombinant IgA kit is a semi-quantitative Enzyme Linked Immunosorbent assay (ELISA) for the determination of species specific IgA antibodies to Mycoplasma pneumoniae in human serum. Savyon® SeroMP™ Recombinant IgA kit is used as an aid in the identification of Mycoplasma pneumoniae infection.
Background/Introduction: M.pneumoniae is a common cause of community-acquiredpneumonia, often characterized by gradual onset ofheadache, fever, malaise and, most typically, dry cough. M.pneumoniae is common in all age groups, however, it ismost common in the first two decades of life and is rare inchildren under the age of four. It has been reported as thecause of up to 30% of all pneumonia cases (2). M.pneumoniae has also been associated with nonrespiratory diseases as meningitis, encephalitis, pancreatitis,sensorineural hearing loss, and acute brainstem syndrome(5). Due to its common occurrence, one should consider M.pneumoniae in all cases of pneumonia, but being the samesymptoms for different agents, additional test tools,such as serological tests, are required (3). The ELISA technique is sensitive, specific and enables adifferential determination of specific IgG, IgA and IgMantibodies (6). In respect to identification and treatment, the most prominent structural feature of MP is the lack of a cell wall. It has been shown that surface-exposed polypeptides elicit an immunogenic response, in particular those that are involved in the attachment organelle of MP. This attachment organelle is composed of a complex of polypeptides, in which P1 Cytadhesin Protein has a major role. (1; 4; 10) Due to its high immunogenicity P1 is a paradigm for utilizing a definitive antigen in serology-based test systems, attempting to improve various parameters of assay performance. A common way to improve test performances by using highly immunogenic polypeptides like the P1 is incorporating these polypeptides in the tests as recombinant antigens. Indeed, several polypeptides have been identified in the literature as good candidates for this purpose. (9) M.pneumoniae specific IgM antibodies rise early after onsetof the disease, reach peak levels in one to four weeks, thendecline to testally insignificant levels within a fewmonths (7). Due to the early appearance and relatively shortlifetime of IgM antibodies, their detection allows theidentification of acute infection using a single serum sample.Young patients tend to have higher IgM levels than adults(8). IgG levels rise slower than IgM, but remain elevatedmuch longer, so a significant increase in two consecutivesamples taken at least 2 weeks apart, may indicate currentinfection or re-infection even in the absence of IgM. IgAantibodies are seen at higher levels in elderly patients (7)and may be more useful than IgM for the identification ofcurrent infection in adults (8). Savyon® tests Ltd. has developed semi-quantitativekits utilising recombinant antigens in IgG, IgA ELISA testsand a qualitative kit utilising mixture of recombinant andnative antigen in the IgM ELISA test which enable to followthe change of antibody levels in human sera. The SeroMP™ Recombinant IgG, IgA and IgM tests enableearly and accurate detection of M. pneumoniae infection.
Background/Introduction: M.pneumoniae is a common cause of community-acquiredpneumonia, often characterized by gradual onset ofheadache, fever, malaise and, most typically, dry cough. M.pneumoniae is common in all age groups, however, it ismost common in the first two decades of life and is rare inchildren under the age of four. It has been reported as thecause of up to 30% of all pneumonia cases (2). M.pneumoniae has also been associated with nonrespiratory diseases as meningitis, encephalitis, pancreatitis,sensorineural hearing loss, and acute brainstem syndrome(5). Due to its common occurrence, one should consider M.pneumoniae in all cases of pneumonia, but being the samesymptoms for different agents, additional test tools,such as serological tests, are required (3). The ELISA technique is sensitive, specific and enables adifferential determination of specific IgG, IgA and IgMantibodies (6). In respect to identification and treatment, the most prominent structural feature of MP is the lack of a cell wall. It has been shown that surface-exposed polypeptides elicit an immunogenic response, in particular those that are involved in the attachment organelle of MP. This attachment organelle is composed of a complex of polypeptides, in which P1 Cytadhesin Protein has a major role. (1; 4; 10) Due to its high immunogenicity P1 is a paradigm for utilizing a definitive antigen in serology-based test systems, attempting to improve various parameters of assay performance. A common way to improve test performances by using highly immunogenic polypeptides like the P1 is incorporating these polypeptides in the tests as recombinant antigens. Indeed, several polypeptides have been identified in the literature as good candidates for this purpose. (9) M.pneumoniae specific IgM antibodies rise early after onsetof the disease, reach peak levels in one to four weeks, thendecline to testally insignificant levels within a fewmonths (7). Due to the early appearance and relatively shortlifetime of IgM antibodies, their detection allows theidentification of acute infection using a single serum sample.Young patients tend to have higher IgM levels than adults(8). IgG levels rise slower than IgM, but remain elevatedmuch longer, so a significant increase in two consecutivesamples taken at least 2 weeks apart, may indicate currentinfection or re-infection even in the absence of IgM. IgAantibodies are seen at higher levels in elderly patients (7)and may be more useful than IgM for the identification ofcurrent infection in adults (8). Savyon® tests Ltd. has developed semi-quantitativekits utilising recombinant antigens in IgG, IgA ELISA testsand a qualitative kit utilising mixture of recombinant andnative antigen in the IgM ELISA test which enable to followthe change of antibody levels in human sera. The SeroMP™ Recombinant IgG, IgA and IgM tests enableearly and accurate detection of M. pneumoniae infection.
Similar Products
Product Notes
The Human IgA (Catalog #AAA490385) is an ELISA Kit and is intended for research purposes only. The product is available for immediate purchase. The AAA490385 ELISA Kit recognizes Human IgA. AAA Biotech's Mycoplasma pneumoniae IgA can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA). Researchers should empirically determine the suitability of the IgA for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "Mycoplasma pneumoniae IgA, ELISA Kit" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
